October 9, 2014—Brand-name drug manufacturers filed suit in federal district court today seeking to invalidate the 340B orphan drug exclusion interpretative rule. … [Read more...]
Lawmakers Question Skyrocketing Generic Drug Prices
One common antibiotic's cost rose over 8,000% in just 6 months, they noteOctober 8, 2014—Sen. Bernie Sanders (I-Vt.) and Rep. Elijah E. Cummings (D-Md.) have sent letters to 14 pharmaceutical manufacturers asking them to explain why the prices of some of their generic drugs have risen so sharply. … [Read more...]
Hospitals Rebut Health Affairs Study’s 340B Conclusions
Researchers say their analysis backs arguments made by drug industry and other criticsOctober 7, 2014—Hospitals groups have responded forcefully to a new study in the journal Health Affairs that its authors say supports the position that disproportionate share hospitals increasingly use 340B savings to help themselves at the expense of the poor. … [Read more...]
OPA to Collect 340B Ceiling-Price Information
Long-awaited move required under ACASeptember 30, 2014 --The Office of Pharmacy Affairs published a notice in today’s Federal Register announcing plans to collect pricing information from manufacturers to help verify the accuracy of 340B ceiling prices, as required by the Affordable Care Act. … [Read more...]
Apexus Awarded HRSA’s Prime Vendor Contract
Group will continue to serve as the 340B Prime Vendor five more yearsSeptember 30, 2014—The Health Resources and Services Administration has awarded a five-year contract to Apexus to continue to run the 340B Prime Vendor Program. … [Read more...]
HHS Looks at ACA’s Early Effect on Hospital Uncompensated Care
Less of a burden expected, mainly in Medicaid expansion statesSeptember 25, 2014—Preliminary data on health care reform's Medicaid and insurance coverage expansions suggest some hospitals' uncompensated care burden will lessen in 2014, the U.S. Department of Health and Human Services reports. … [Read more...]
340B Duplicate Discounts a Hot Topic at Drug Industry Conference
Medicaid expansion and move away from fee-for-service toward managed care cited as reasonsSeptember 24, 2014—Medicaid expansion in general and Medicaid managed care growth in particular have drug manufacturers concentrating on 340B duplicate discounts as never before. … [Read more...]